Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab rechallenge followed by regorafenib versus the reverse sequence in RAS/BRAF wild-type chemorefractory metastatic colorectal cancer
2019-002834-35Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab and regorafenib in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Overall survival. Started Oct 2020; status: active.
02
Drugs
panitumumabregorafenib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2019-002834-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002834-35.